ANCA血管炎治疗市场：按类型、药物类型、分销管道和地区划分

2026年ANCA血管炎治疗市场规模估计为5.749亿美元，预计2033年将达到8.363亿美元。预计从2026年到2033年，该市场将以5.5%的复合年增长率成长。

嗜中性白血球球胞浆抗体（ANCA）相关性血管炎（AAV）是一组以微血管发炎和损伤为特征的自体免疫疾病。发炎是由称为ANCA的自身反应性抗体引起的，这些抗体与嗜中性白血球结合併过度激活它们。这种免疫系统功能障碍可能由遗传或环境因素引起。 ANCA血管炎可引起多种症状，取决于受累的器官和身体部位。例如，皮肤血管损伤可导致皮疹。肾臟血管问题会导致血液和蛋白质渗漏到尿液中，甚至造成肾臟损伤。 ANCA血管炎主要分为三种：显微多发性血管炎（MPA）、肉芽肿性多血管炎（GPA）和嗜酸性粒细胞多血管炎（EGPA）。目前，该疾病尚无治癒方法，但有治疗方法可以控制症状。患者通常需要经历两个治疗阶段。第一种治疗方法是诱导症状缓解（诱导治疗），第二种治疗方法是尽可能长时间维持缓解状态（维持治疗）。

市场动态

市场主要企业正专注于研发活动，并致力于在各类医学会议上展示其研究成果，预计这将推动预测期内的市场成长。例如，2022年5月，生物製药公司ChemoCentryx宣布计画在三场重要的医学会议上发表报告。这些报告将涵盖ADVOCATE III期临床试验的结果，该试验证实了口服选择性补体5a受体（C5aR）抑制剂Tavneos（avacopan）的核准，以及一项关于糖皮质激素在ANCA相关性血管炎中应用负担的研究。这三场会议分别是：2022 年美国胸腔科协会年会（ATS 2022，2022 年 5 月 15 日至 17 日，旧金山）、2022 年国际药物经济学与结果研究学会年会（ISPOR 2022，2022 年 5 月 15 日至 18 日，华盛顿年会年 5 月 19 日至 22 日，法国巴黎/线上）。

本次调查的主要特点

• 本报告对全球 ANCA 血管炎治疗市场进行了详细分析，以 2025 年为基准年，给出了预测期（2026-2033 年）的市场规模和復合年增长率（%）。
• 本报告指出了各个细分市场的潜在商机，并说明了该市场中具有吸引力的投资提案矩阵。
• 此外，本研究还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
• 本报告根据以下参数对全球 ANCA 血管炎治疗市场的主要企业进行了分析：公司概况、产品系列、主要亮点、财务表现和策略。
• 透过利用本报告中提出的见解，企业行销负责人和经营团队可以就未来的产品发布、产品升级、市场扩张和行销策略做出明智的决策。
• 这份全球 ANCA 血管炎治疗市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
• 透过分析全球 ANCA 血管炎治疗市场中使用的各种策略矩阵，相关人员将能够更轻鬆地做出决策。

目录

第一章：研究目标与前提条件

• 研究目标
• 前提
• 简称

第二章 市场范围

• 报告摘要
  • 市场定义和范围
• 执行摘要

第三章：市场动态、监管与趋势分析

• 市场动态
  • 促进因素
  • 抑制因子
  • 市场机会
• 影响分析
• 市场趋势
• 主要进展
• 法规环境
• PEST分析
• 流行病学
• 产品上市及核准

第四章 全球ANCA血管炎治疗市场：按类型划分，2026-2033年

• 概述
• 肉芽肿性多血管炎（GPA）
• 显微镜下多血管炎（MPA）
• 嗜酸性粒细胞多血管炎（EGPA）
• 肾臟局限性血管炎

第五章 全球ANCA相关性血管炎治疗市场：依药物类型划分，2026-2033年

• 概述
• 糖皮质激素
• Cyclophosphamide
• Rituximab
• 胺基甲基叶酸
• Mycophenolate Mofetil
• Azathioprine
• 美泊利单抗
• 阿巴科潘
• 其他的

第六章 全球ANCA血管炎治疗市场：依通路划分，2026-2033年

• 概述
• 医院药房
• 零售药房
• 网路药房

第七章 全球ANCA血管炎治疗市场：依地区划分，2026-2033年

• 北美洲
  • 我们
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
• 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
• 中东
  • GCC
  • 以色列
  • 其他中东国家
• 非洲
  • 北非
  • 中非
  • 南非

第八章 竞争情势

• ChemoCentryx, Inc.
• Vifor Pharma
• GlaxoSmithKline plc
• Amgen
• Genentech, Inc.
• Pfizer Inc.
• Biogen
• InflaRx GmbH
• AstraZeneca

第九章

• 调查方法
• 关于本公司

Anca Vasculitis Drug Market is estimated to be valued at USD 574.9 Mn in 2026 and is expected to reach USD 836.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.5% from 2026 to 2033.

Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a group of autoimmune diseases characterized by inflammation and damage to small blood vessels. Self-reactive antibodies known as ANCAs, which bind to and excessively activate neutrophils, are the cause behind this inflammation. This immune system malfunction is caused by hereditary and environmental factors. ANCA vasculitis can result in a variety of symptoms depending on the organ or body part affected. For instance, if the skin's blood vessels are harmed, a rash may result. Blood and protein leakage into the urine as well as kidney damage can result from problems with the blood vessels in the kidney. There are three main types of ANCA vasculitis, microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Currently, there is no cure for the disease and treatments are available to manage the condition. Patients normally undergo two phases of treatment, one designed to induce the remission of symptoms (induction treatment), and a second phase meant to keep patients in remission for as long as possible (maintenance treatment).

Market Dynamics

Key players in market are focused on carrying out research and development activities and demonstrating the results of the studies at various medical conferences, which is expected to drive the market growth over the forecast period. For instance, in May 2022, ChemoCentryx, Inc., a biopharmaceutical company, announced upcoming presentations at three key medical conferences that would highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of tavneos (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and research into the burden of glucocorticoid use in ANCA-associated vasculitis. The three conferences were ATS 2022 (American Thoracic Society), May 15-17, 2022, San Francisco, ISPOR 2022 (International Society for Pharmacoeconomics and Outcomes Research), May 15-18, 2022, Washington, and 59th ERA Conference (European Renal Association), May 19-22, 2022, Paris, France/Virtual

Key features of the study

• This report provides in-depth analysis of the global ANCA vasculitis drug market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global ANCA vasculitis drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include ChemoCentryx, Inc., Vifor Pharma, GlaxoSmithKline plc, Amgen, Genentech, Inc., Pfizer Inc., Biogen, InflaRx GmbH, and AstraZeneca
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global ANCA vasculitis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ANCA vasculitis drug market

Market Segmentation

• Global ANCA Vasculitis Drug Market, By Type
  • Granulomatosis with Polyangiitis (GPA)
  • Microscopic Polyangiitis (MPA)
  • Eosinophilic Granulomatosis with Polyangiitis (EGPA)
  • Renal-limited Vasculitis
• Global ANCA Vasculitis Drug Market, By Drug Type
  • Glucocorticoids
  • Cyclophosphamide
  • Rituximab
  • Methotrexate
  • Mycophenolate mofetil
  • Azathioprine
  • Mepolizumab
  • Avacopan
  • Others
• Global ANCA Vasculitis Drug Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global ANCA Vasculitis Drug Market, By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa
  • GCC Countries
  • Israel
  • Rest of Middle East & Africa
• Key Players
  • ChemoCentryx, Inc.
  • Vifor Pharma
  • GlaxoSmithKline plc
  • Amgen
  • Genentech, Inc.
  • Pfizer Inc.
  • Biogen
  • InflaRx GmbH
  • AstraZeneca.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Country
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• PEST Analysis
• Epidemiology
• Product Launch/Approvals

4. Global ANCA Vasculitis Drug Market, By Type, 2026 - 2033, (USD Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Granulomatosis with Polyangiitis (GPA)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Microscopic Polyangiitis (MPA)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Eosinophilic Granulomatosis with Polyangiitis (EGPA)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Renal-limited Vasculitis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

5. Global ANCA Vasculitis Drug Market, By Drug Type, 2026 - 2033, (USD Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Glucocorticoids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Cyclophosphamide
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Rituximab
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Methotrexate
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Mycophenolate mofetil
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Azathioprine
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Mepolizumab
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Avacopan
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

6. Global ANCA Vasculitis Drug Market, By Distribution Channel, 2026 - 2033, (USD Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

7. Global ANCA Vasculitis Drug Market, By Region, 2026 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2026-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • UK
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• ChemoCentryx, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Vifor Pharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• GlaxoSmithKline plc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Amgen
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Genentech, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Biogen
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• InflaRx GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

9. Section

• Research Methodology
• About Us